Revenues

3 Months Ended

Mar. 31, 2020

Revenue from Contract with Customer [Abstract]

Revenues

Revenues

We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. Rest-of-world (ROW) revenues relate to products that are sold primarily in Europe.

Revenues were as follows (in millions):

	Three months ended March 31,
	2020						2019
	US		ROW		Total		US		ROW		Total
Enbrel® (etanercept)	$	1,117	$	36	$	1,153	$	1,106	$	45	$	1,151
Prolia® (denosumab)	422		232		654		390		202		592
Neulasta® (pegfilgrastim)	534		75		609		893		128		1,021
XGEVA® (denosumab)	355		126		481		356		115		471
Otezla® (apremilast)	377		102		479		—		—		—
Aranesp® (darbepoetin alfa)	175		247		422		182		232		414
KYPROLIS® (carfilzomib)	187		93		280		154		91		245
Repatha® (evolocumab)	124		105		229		83		58		141
Other products	988		599		1,587		827		424		1,251
Total product sales(1)	$	4,279	$	1,615	5,894		$	3,991	$	1,295	5,286
Other revenues					267						271
Total revenues					$	6,161					$	5,557

^____________ 

⁽¹⁾ 

Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2020 and 2019.